Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : CONSOLIDATED STATEMENT OF INCOME - GAAP (Form 8-K)

06/21/2021 | 04:45pm EDT
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
On June 2, 2021, Merck completed the spinoff of products from its women's health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon's publicly traded stock to company shareholders. The historical results of the women's health, biosimilars and established brands businesses that were contributed to Organon in the spinoff are excluded from sales and expenses below and reflected as discontinued operations in the company's Consolidated Statements of Income provided below.
2021 2020 2019
1Q 1Q 2Q 3Q 4Q Full Year Full Year
Sales $ 10,627 $ 10,288 $ 9,353 $ 10,929 $ 10,948 $ 41,518 $ 39,121
Costs, Expenses and Other
Cost of sales 3,199 2,829 2,747 3,013 5,029 13,618 12,016
Selling, general and administrative 2,187 2,191 2,085 2,060 2,619 8,955 9,455
Research and development 2,412 2,175 2,085 3,349 5,788 13,397 9,724
Restructuring costs 297 70 82 113 310 575 626
Other (income) expense, net (455 ) 62 (387 ) (312 ) (253 ) (890 ) 129
Income (Loss) from Continuing Operations Before Taxes 2,987 2,961 2,741 2,706 (2,545 ) 5,863 7,171
Income Tax Provision 238 495 396 380 69 1,340 1,565
Net Income (Loss) from Continuing Operations 2,749 2,466 2,345 2,326 (2,614 ) 4,523 5,606
Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 (5 ) 4 2 3 4 (84 )
Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. 2,745 2,471 2,341 2,324 (2,617 ) 4,519 5,690
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 434 749 662 617 521 2,548 4,153
Net Income (Loss) Attributable to Merck & Co., Inc. $ 3,179 $ 3,220 $ 3,003 $ 2,941 $ (2,096 ) $ 7,067 $ 9,843
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations $ 1.08 $ 0.98 $ 0.93 $ 0.92 $ (1.03 ) $ 1.79 $ 2.22
Income from Discontinued Operations 0.17 0.30 0.26 0.24 0.21 1.01 1.62
Net Income (Loss) $ 1.26 $ 1.27 $ 1.19 $ 1.16 $ (0.83 ) $ 2.79 $ 3.84
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income (Loss) from Continuing Operations $ 1.08 $ 0.97 $ 0.92 $ 0.92 $ (1.03 ) $ 1.78 $ 2.21
Income from Discontinued Operations 0.17 0.29 0.26 0.24 0.21 1.00 1.61
Net Income (Loss) $ 1.25 $ 1.26 $ 1.18 $ 1.16 $ (0.83 ) $ 2.78 $ 3.81
Average Shares Outstanding Assuming Dilution (1) 2,541 2,547 2,536 2,538 2,530 2,541 2,580
Tax Rate from Continuing Operations 8.0 % 16.7 % 14.4 % 14.0 % -2.7 % 22.9 % 21.8 %
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

(1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding.

MERCK & CO., INC.

FIRST QUARTER 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1)
Restructuring Costs (2) (Income) Loss from
Investments in Equity
Securities
Certain Other Items Adjustment Subtotal Non-GAAP
First Quarter
Cost of sales $ 3,199 497 27 188 (3) 712 $ 2,487
Selling, general and administrative 2,187 10 3 13 2,174
Research and development 2,412 18 7 25 2,387
Restructuring costs 297 297 297 -
Other (income) expense, net (455 ) (28 ) (561 ) (589 ) 134
Income From Continuing Operations Before Taxes 2,987 (497 ) (334 ) 561 (188 ) (458 ) 3,445
Income Tax Provision (Benefit) 238 (89 )(4) (41 )(4) 123 (4) (249 )(4) (256 ) 494
Net Income from Continuing Operations 2,749 (408 ) (293 ) 438 61 (202 ) 2,951
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,745 (408 ) (293 ) 438 61 (202 ) 2,947
Earnings per Common Share Assuming Dilution from Continuing Operations $ 1.08 (0.16 ) (0.11 ) 0.17 0.02 (0.08 ) $ 1.16
Tax Rate 8.0 % 14.3 %
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets. Amount included in selling, general and administrative expenses reflects acquisition and divestiture-related costs. Amount included in other (income) expense, net, primarily reflects royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents a charge for the discontinuation of COVID-19 development programs.
(4) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items also include a $208 million net tax benefit related to the settlement of certain federal income tax matters.

MERCK & CO., INC.

2020 GAAP TO NON-GAAP RECONCILIATIONS - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below.

GAAP

Acquisition and Divestiture-

Related Costs (1)

Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal Non-GAAP
Full Year
Cost of sales $ 13,618 3,355 175 260 (6) 3,790 $ 9,828
Selling, general and administrative 8,955 225 47 272 8,683
Research and development 13,397 12 83 4,243 (4)(7) 4,338 9,059
Restructuring costs 575 575 575 -
Other (income) expense, net (890 ) 50 (1,292 ) (20 ) (1,262 ) 372
Income From Continuing Operations Before Taxes 5,863 (3,642 ) (880 ) 1,292 (4,483 ) (7,713 ) 13,576
Income Tax Provision (Benefit) 1,340 (627 )(3) (80 )(3) 284 (3) (303 )(3) (726 ) 2,066
Net Income from Continuing Operations 4,523 (3,015 ) (800 ) 1,008 (4,180 ) (6,987 ) 11,510
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,519 (3,015 ) (800 ) 1,008 (4,180 ) (6,987 ) 11,506
Earnings per Common Share Assuming Dilution Attributable to Continuing Operations $ 1.78 (1.19 ) (0.31 ) 0.40 (1.65 ) (2.75 ) $ 4.53
Tax Rate 22.9 % 15.2 %
First Quarter
Cost of sales $ 2,829 387 68 455 $ 2,374
Selling, general and administrative 2,191 113 11 124 2,067
Research and development 2,175 40 17 57 2,118
Restructuring costs 70 70 70 -
Other (income) expense, net 62 (11 ) (87 ) (98 ) 160
Income From Continuing Operations Before Taxes 2,961 (529 ) (166 ) 87 (608 ) 3,569
Income Tax Provision (Benefit) 495 (150 )(3) (7 )(3) 19 (3) (138 ) 633
Net Income from Continuing Operations 2,466 (379 ) (159 ) 68 (470 ) 2,936
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,471 (379 ) (159 ) 68 (470 ) 2,941
Earnings per Common Share Assuming Dilution from Continuing Operations $ 0.97 (0.15 ) (0.06 ) 0.03 (0.18 ) $ 1.15
Tax Rate 16.7 % 17.7 %
Second Quarter
Cost of sales $ 2,747 580 25 605 $ 2,142
Selling, general and administrative 2,085 44 11 55 2,030
Research and development 2,085 (63 ) 31 (32 ) 2,117
Restructuring costs 82 82 82 -
Other (income) expense, net (387 ) 63 (511 ) (16 ) (464 ) 77
Income From Continuing Operations Before Taxes 2,741 (624 ) (149 ) 511 16 (246 ) 2,987
Income Tax Provision (Benefit) 396 (91 )(3) (27 )(3) 112 (3) 5 (3) (1 ) 397
Net Income from Continuing Operations 2,345 (533 ) (122 ) 399 11 (245 ) 2,590
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,341 (533 ) (122 ) 399 11 (245 ) 2,586
Earnings per Common Share Assuming Dilution from Continuing Operations $ 0.92 (0.21 ) (0.05 ) 0.16 - (0.10 ) $ 1.02
Tax Rate 14.4 % 13.3 %
Third Quarter
Cost of sales $ 3,013 403 38 441 $ 2,572
Selling, general and administrative 2,060 25 15 40 2,020
Research and development 3,349 19 19 1,082 (4) 1,120 2,229
Restructuring costs 113 113 113 -
Other (income) expense, net (312 ) (346 ) (1 ) (347 ) 35
Income From Continuing Operations Before Taxes 2,706 (447 ) (185 ) 346 (1,081 ) (1,367 ) 4,073
Income Tax Provision (Benefit) 380 (9 )(5) (25 )(3) 76 (3) (247 )(3) (205 ) 585
Net Income from Continuing Operations 2,326 (438 ) (160 ) 270 (834 ) (1,162 ) 3,488
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 2,324 (438 ) (160 ) 270 (834 ) (1,162 ) 3,486
Earnings per Common Share Assuming Dilution Attributable to Continuing Operations $ 0.92 (0.17 ) (0.06 ) 0.11 (0.33 ) (0.45 ) $ 1.37
Tax Rate 14.0 % 14.4 %
Fourth Quarter
Cost of sales $ 5,029 1,986 44 260 (6) 2,290 $ 2,739
Selling, general and administrative 2,619 42 10 52 2,567
Research and development 5,788 16 16 3,161 (7) 3,193 2,595
Restructuring costs 310 310 310 -
Other (income) expense, net (253 ) (2 ) (348 ) (3 ) (353 ) 100
Loss From Continuing Operations Before Taxes (2,545 ) (2,042 ) (380 ) 348 (3,418 ) (5,492 ) 2,947
Income Tax Provision (Benefit) 69 (378 )(3) (21 )(3) 77 (3) (61 )(3) (383 ) 452
Net Loss from Continuing Operations (2,614 ) (1,664 ) (359 ) 271 (3,357 ) (5,109 ) 2,495
Net Loss from Continuing Operations Attributable to Merck & Co., Inc. (2,617 ) (1,664 ) (359 ) 271 (3,357 ) (5,109 ) 2,492
Loss per Common Share Assuming Dilution Attributable to Continuing Operations (8) $ (1.03 ) (0.66 ) (0.14 ) 0.11 (1.32 ) (2.01 ) $ 0.98
Tax Rate -2.7 % 15.4 %

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets and, for the fourth quarter and full year of 2020, also include a $1.6 billion intangible asset impairment charge related to ZERBAXA. Amounts included in selling, general and administrative (SG&A) expenses reflect acquisition and divestiture-related costs, including $95 million in the first quarter of 2020 related to the acquisition of Arqule, Inc. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration and royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

(4) Reflects expenses for upfront payments related to license and collaboration agreements.

(5) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Also includes a tax cost of $67 million representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition.

(6) Reflects a charge for the discontinuation of COVID-19 development programs.

(7) Reflects charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19 vaccine development programs.

(8) Because the company recorded a net loss in the period, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.

MERCK & CO., INC.

2019 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1)

Restructuring Costs (2)

(Income) Loss from
Investments in Equity
Securities
Certain Other Items Adjustment Subtotal Non-GAAP
Full Year
Cost of sales $ 12,016 2,404 251 2,655 $ 9,361
Selling, general and administrative 9,455 126 34 160 9,295
Research and development 9,724 156 4 993 (4) 1,153 8,571
Restructuring costs 626 626 626 -
Other (income) expense, net 129 284 (132 ) 55 207 (78 )
Income From Continuing Operations Before Taxes 7,171 (2,970 ) (915 ) 132 (1,048 ) (4,801 ) 11,972
Income Tax Provision (Benefit) 1,565 (540 )(3) (152 )(3) 29 (3) (122 )(5) (785 ) 2,350
Net Income from Continuing Operations 5,606 (2,430 ) (763 ) 103 (926 ) (4,016 ) 9,622
Less: Net (Loss) Income Attributable to Noncontrolling Interests (84 ) (89 ) (89 ) 5
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 5,690 (2,341 ) (763 ) 103 (926 ) (3,927 ) 9,617
Earnings per Common Share Assuming Dilution Attributable to Continuing Operations $ 2.21 (0.91 ) (0.29 ) 0.04 (0.36 ) (1.52 ) $ 3.73
Tax Rate 21.8 % 19.6 %
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management's annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amount included in cost of sales primarily reflects expenses for the amortization of intangible assets, as well as $705 million of intangible asset impairment charges, including $612 million related to SIVEXTRO. Amount included in selling, general and administrative expenses primarily reflects integration, transaction and certain other costs related to business acquisitions and divestitures, including costs related to the acquisition of Antelliq Corporation. Amount included in research and development expenses primarily reflects $172 million of in-process research and development (IPR&D) impairment charges, partially offset by a reduction in expenses related to a decrease in the estimated fair value measurement of liabilities for contingent consideration. Amount included in other (income) expense, net, primarily reflects goodwill and intangible asset impairment charges related to certain businesses in the Healthcare Services segment and expenses related to an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Amount included in research and development represents the charge related to the acquisition of Peloton Therapeutics, Inc.
(5) Primarily reflects a $106 million net tax benefit related to the settlement of certain federal income tax matters, an $86 million tax benefit related to the reversal of tax reserves established in conjunction with the divestiture of Merck's Consumer Care business in 2014 as a result of the lapse in the statute of limitations, and a $117 million tax charge related to the finalization of treasury regulations associated with the 2017 enactment of U.S. tax legislation.

Disclaimer

Merck & Co. Inc. published this content on 21 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2021 20:44:01 UTC.


ę Publicnow 2021
All news about MERCK & CO., INC.
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
AQ
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
MT
07/22MERCK : Eisai Win US FDA Approval of Keytruda Plus Lenvima Combination for Certa..
MT
07/22MERCK : FDA Approves KEYTRUDA« (pembrolizumab) Plus LENVIMA« (lenvatinib) Combin..
BU
07/22FDA Approves KEYTRUDA« (pembrolizumab) Plus LENVIMA« Combination for Patients..
CI
07/21MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in..
MT
07/21NOXXON Pharma N.V. Enters Second Clinical Collaboration with Merck & Co., Inc..
CI
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
MT
07/21MERCK : Secures European Approval for Verquvo for Chronic Heart Failure
MT
07/21MERCK : VERQUVO« (vericiguat) Approved in the European Union
BU
More news
Financials (USD)
Sales 2021 46 551 M - -
Net income 2021 12 867 M - -
Net Debt 2021 11 752 M - -
P/E ratio 2021 16,5x
Yield 2021 3,39%
Capitalization 196 B 196 B -
EV / Sales 2021 4,45x
EV / Sales 2022 4,05x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,24 $
Average target price 94,10 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.21%195 475
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246